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ABSTRACT 
Hemodynamic and hematologic effects of protamine reversal of low 
molecular weight heparin (LMWH) anticoagulation with and without 
protamine pretreatment, as well as reversal of anticoagulation with 
unfractionated standard heparin (SH), were studied in canine 
subjects. Protamine reversal caused less severe thrombocytopenia in 
the two LMWH groups compared to SH animals, while neutropenia occurred 
equally in all groups. Cl-esterase inhibitor levels were minimally 
increased, whereas C3 levels and leucotriene levels were unaltered. 
TxB2 and 6-keto-PGFl, increased during protamine reversal of LMWH 
anticoagulation. TCT and APTT were affected less with LMWH than SH 
anticoagulation. Anti-Xa levels increased with anticoagulation in all 
animals, but protamine did not reverse the elevated anti-Xa levels in 
LMWH anticoagulated dogs to the same degree as occurred with SH 
anticoagulation. TCT, APTT and bleeding times were normalized by 
protamine in all animals. Protamine reversal of LMWH anticoagulation 
with or without protamine pretreatment did not reveal any clear 
differences in eicosanoids or complement factors compared to SH 
anticoagulation, although differences in anti-Xa activity clearly 
separated these two heparins. 
INTRODUCTION 
Protamine sulfate reverses heparin anticoagulation by dissociation of 
heparin-antithrombin III complexes and the formation of protamine-heparin 
complexes. Protamine sulfate may also cause systemic hypotension, 
bradycardia, pulmonary artery hypertension, thrombocytopenia, and neutropenia, 
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as well as allergic and anaphylactic-like reactions during heparin reversal 
(1,2). The exact mechanisms by which these adverse side effects occur have 
not been clearly defined. 
In contrast to unfractionated standard heparin (SH), the antithrombotic 
potential of low molecular weight heparin (LMWH) depends on inhibition of 
factor Xa, and has a lesser effect on factor IIa. In addition, LMWH appears 
to have less of an effect on platelets. Pharmacokinetically, anticoagulant 
levels of LNWH remain detectable for longer periods of time than with SH. 
Other potential advantages of LHWH over SH include fewer disturbances of liver 
function and lipolysis, as well as a lesser demineralizing effect on the 
skeleton (3). 
Recently it was demonstrated that pretreatment with a small dose of 
protamine before subsequent reversal of SH anticoagulation reduced the adverse 
hemodynamic and hematologic side effects usually accompanying such reversal. 
The hemodynamic effects of protamine reversal of anticoagulation achieved with 
LMWH as well as with SH have recently been assessed with and without protamine 
pretreatment (1.2). The current study investigates changes in eicosanoids, 
clotting, and complement factors occurring with reversal of SH and LMWH 
anticoagulation in an experimental canine model in which a prosthetic graft 
was placed in the infrarenal aortic position. 
MATERIALS AND METHODS 
Eighteen mongrel dogs of both sexes were prepared for study: Group I 
(n=6) received LMWH following saline pretreatment, Group II (n=6) received 
LMWH following protamine pretreatment, and Group III (n=6) received SH 
following saline pretreatment. All animals were anesthetized with sodium 
pentobarbital (30 mg/kg) and mechnically ventilated. Hydration was maintained 
by administration of lactated ringers solution, as a 20 ml/kg bolus followed 
by a 10 ml/kg/hour infusion. An inferior vena cava catheter was placed 
transfemorally for blood sampling. Drug administration was performed through 
a separate peripheral intravenous cannula. Systemic arterial blood pressure 
measurements were made using a catheter in the femoral artery, while pulmonary 
artery pressures and cardiac output determinations were accomplished with a 
Swan Ganz catheter threaded from the femoral vein into the pulmonary artery. 
The infrarenal aorta was exposed through a midline abdominal incision for 
placement of a 6 mm ID Dacron double velour aortic interposition graft, 5 to 7 
cm length. 
Protamine or saline pretreatment was randomly administered to study 
subjects in a blinded fashion. Protamine pretreatment consisted of 2.25 mg/kg 
protamine sulfate (Upjohn Inc., Kalamazoo, MI. USA) divided into three equal 
doses (0.75 mg/kg) given at 2 minute intervals prior to heparin 
administration. An equal volume of 0.9N NaCl solution was administered in the 
saline pretreatment groups. Anticoagulation was then achieved with LMWH or 
SH. Heparin was administered 3 minutes following completion of pretreatment, 
and 3 minutes later the aorta was clamped. 
The LMWH fragment used in this study was obtained by partial degradation 
of porcine intestinal mucosal heparin with nitrous acid and isolated by 
ethanol precipitation. LMWH antiXa activity was 4.1 times its APTT activity. 
This LMWH had a medium molecular weight of 4,000-5,000 (Kabi 2165, Kabi. AB, 
Sweden). LMWH was given in a dose of 150 U antiXa/kg. SH of beef lung origin 
was administered in a dose of 150 IU/kg (UpJohn Inc., Kalamazoo, MI, USA). 
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Five minutes after completing the insertion of the aortic prosthesis 
intravenous protamine sulfate (1.5 mg/kg) was administered over a 10 second 
time period. Blood samples for biochemical and hematological studies were 
obtained at baseline, 2 minutes after protamine pretreatment, 2 minutes after 
heparin anticoagulation, as well as immediately before and 1, 3 and 10 minutes 
after protamine reversal. 
Platelet and white blood cell counts were performed using standard 
techniques. U2-macroglobulin was assayed semiquantitatively by titration of 
plasma samples with porcine trypsin using N-Benzoyl-DL-Arginine-p-Nitro- 
aniline (4) (8apNA. Sigma Chemical Co., St. Louis, HO, USA). C-1-esterase 
inhibitor (Chromogenic substrate S-2302, Kabi AB, Sweden) was determined 
according to the technique of Gallimore and Friberger (5). Antithrombin III 
analysis (Chromogenic substrate S-2238, Kabi A8, Sweden) was performed as 
described by Abildgaard et al (6). Heparin activity was assessed by anti-Xa 
analysis (Chromogenic substrate S-2222, Kabi A8, Sweden) as reported by Teien 
et al. (7). All chromogenic substrate assays were endpoint assays. Standard 
curves were made from pooled baseline plasma. Beef heparin related to 3rd 
Int. Std. was used. C3 was determined by electroimmunophoresis (8). 
TABLE 1. 
Platelet and White Blood Cell Counts Accompanying Protamine 
Reversal of Anticoagulation 
Group I Group II Group III 
LHWH, LHWH, SH. 
Saline Protamine Saline 
Pretreatment Pretreatment Pretreatment 
- 
Platelet Count (103/,L) 
Baseline 253233 210230 231+49 
After pretreatment 266+35 170+_24** 228231 
After heparinization 248+30 159+19* 258244 
Before reversal (rev.) 271540 200225 259+43 
1 minute after rev. 176+39*** 103+10* 67+21*** 
3 minutes after rev. 111+14*** 103229** 96+20** 
10 minutes after rev. 131+23*** 100+21** 86+9** 
- 
White Blood Cell Count (103/,L) 
Baseline 8.8k1.4 6.321.4 7.5to.5 
After pretreatment 9.Ot1.6 6.421.6 6.1kO.3 
After heparinization 7.221.3 7.722.1 7.2k1.5 
Before reversal (rev.) 7.551.1 8.5k1.6 7.421.3 
1 minute after rev. 3.6fp.6* 3.3+0.5* 3.320.6* 
3 minutes after rev. 4.6kO.8 6.020.7 5.8+1.0 
10 minutes after rev. 7.7kl.l 7.421.1 8.621.4 
Data expressed as x t SEH; n=6 in each group; Intragroup differences *p<O.O5. 
**p<o.o1, ***p<o.o01. 
Eicosanoid activity was quantitated in plasma after extraction of proteins 
and free fatty acids. Hetabolites of prostacyclin (6-keto-PGFl,) and 
thromboxane (Tx82) were measured by radioimnunoassay (New England Nuclear, 
detection limit 3.8 pg and 0.5 pg, respectively). Cross-reactivity to these 
related eicosanoids was low. Leucotrienes C4 and 84 were also measured 
using radioimnunoassay technique (New England Nuclear kit, detection limit 3.3 
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pg and 1.5 pg. respectively). Statistical analyses 
for intragroup paired data and Wilcoxon rank sum 
comparisons. 
RESULTS 
included student's t-test 
test for intergroup data 
Protamine reversal of anticoagulation produced reductions in platelet 
counts (-59X, -50%. -74%) and white blood cell counts (-52%. -61%. -55%) in 
groups I, II and III, respectively (Table 1). Depressed platelet counts 
persisted during the study, but white blood cell counts generally normalized 
within 10 minutes. Protamine pretreatment in and of itself (Group II) 
produced a slight reduction (-19%) in platelet count but no effect on the 
white blood cell count. 
Antithrombin III and a-2macroglobulin levels were essentially unchanged 
following protamine reversal in groups I and II (Table 2). Anti-Xa levels 
were greater than 1.0 heparin U/ml after heparinization in all 3 groups. 
Anti-Xa activity returned to baseline in group III animals but remained 
elevated in both groups of animals anticoagulated with LMWH (Table 3). 
C-1-esterase inhibitor levels were not statistically changed after 
protamine reversal in any group, but did tend to increase at 1 and 3 minutes 
after reversal. C3 activity did not change significantly in any of the groups 
(Table 4). 
6-keto-PGFl, levels increased during aortic clamping (+123X) and 
increased further after reversal in group I. There was no increase in 
6-keto-PGFl, during clamping in group II although there was an increase with 
protamine reversal of heparin (Table 5). Protamine reversal caused increased 
activities of TX62 in group I compared to group II (Table 5). LTB4 and 
LTC4 levels were not significantly altered (Table 6). 
Different assays regarding anticoagulation were used in addition to XaI 
measurements (Table 7). SH had a more pronounced effect on TCT and APTT then 
LHWH. LMWH with protamine pretreatment (Group II) affected APTT and TCT less 
than with saline pretreatment (Group I), although the same effect on factor 
XaI was observed (Table 3). 
TABLE 2. 
Antithrombin III and a2-Macroglobulin Levels 
During Anticoagulation With Low Molecular Weight Heparin and Pretreatment 
With or Without Protamine and Subsequent Protamine Reversal of Anticoagulation 
Group I Group II Group I Group II 
LHWH, LHWH, LMWH, LMWH, 
Saline Protamine Saline Protamine 
Pretreatment Pretreatment Pretreatment Pretreatment 
Antithrombin III (Xl a2-Macroglobulin (mg/ml) 
Baseline values 8525 86+8 
After pretreatment 86+6 9556 
After LMWH 8654 97fp 
Before reversal (rev.) 83+5 8855 4.4to.5 3.7io.3 
1 minute after rev. 8654 91+6 4.020.5 3.850.4 
3 minutes after rev. 73+8 8857 4.1to.5 3.8tO.4 
10 minutes after rev. 74+9 88+s 4.1to.4 4.020.4 
Data expressed as x 5 SEM; n=6 in each group 
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Ant iXa (Hepar 
TABLE 3. 
in Ill/ml) Levels During Anticoagulation with Low Molecular 
Weight Heparin with or Without Pretreatment with Protamine Before 
Subsequent Protamine Reversal of Anticoagulation 
- 
Group I Group II Group III 
LHWH, LMWH, SH, 
Saline Protamine Saline 
Pretreatment Pretreatment Pretreatment 
Baseline 0 0 0 
After pretreatment 0.02+0.03* 0.01+0.02 _ 
After heparin 1.09+0.13** 1.12+0.08** 1.46 
Before reversal (rev.) 1.16+0.09** 1.23kO.14" 1.34 
1 minute after rev. O.El~O.ll* 0.90+0.19* 0.06 
3 minutes after rev. 0.72+0.14* 0.86+0.13* 0.08 
10 minutes after rev. 0.98+0.14* 0.89+0.13* 0.01 
Eta expressed as x t SEM; n=6 in Groups I and II, n=2 in Group III. 
*p<o.o1, **p<o.o01 
Comparison with Group III not possible because of small numbers. 
TABLE 4. 
C-1-esterase Inhibitor and C3 Levels During Anticoagulation 
With Low Molecular Weight Heparin or Standard Heparin and Pre- 
treatment With or Without Protamine and Subsequent Protamine Reversal 
-. 
Group I Group II Group III 
LMWH, LMWH, SH, 
Saline Protamine Saline 
Pretreatment Pretreatment Pretreatment 
-- -__ 
C-l<sterase Inhibitor (X) 
Baseline 89+8 10125 102 
After pretreatment 91i9 130+13 
After anticoagulation 121523 165?28* 91 
Before reversal (rev.) 89+16 136+23 71 
1 minute after rev. 135227 152+19 148 
3 minutes after rev. 121+22 166528 120 
10 minutes after rev. 79+20 126518 96 
C3 (%) 
Baseline 104+11 108+11 129 
After pretreatment 99512 106~10 
After anticoagulation 107+13 105+10 130 
Before reversal (rev). lOl+s 102+7 133 
1 minute after rev. 93+11 10125 114 
3 minutes after rev. 104+9 93512 98 
10 minutes after rev. 104+12 97+8 88 
Eta expressed as x + SEM; n=6 in Groups I and II, n=2 in Group III; *p<O.O5 
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TABLE 5. 
6-keto-PGFl, and Tx82 Levels During Anticoagulation 
With Low Molecular Heparin and Pretreatment With or Without 
Protamine and Subsequent Protamine Reversal of Anticoagulation 
Group I Group II Group I Group II 
LMWH, LNWH, LMWH, LMWH, 
Saline, Protamine Saline Protamine 
Pretreatment Pretreatment Pretreatment Pretreatment 
6-keto-PGFl, (pg/ml) TxB:, (&ml)_ 
Baseline value 210t50 186+32 1173+245 739+133 
After pretreatment 197+37 154+50 11855287 1187+320 
After heparin 469+3*a 182+35 1284+226 815+193 
before reversal (rev.) 
1 minute after rev. 310+69 246244 4813+1127*a 1782+515* 
3 minutes after rev. 617+95**a 
475i81*a 
329+51 341221291 1493+489 
10 minutes after rev. 283235 1706+252 1136~268 
Data expressed as x t SEN, n=6 in each group; *p<O.O5, **p<O.Ol, 
aintergroup difference ~~0.05 
TABLE 6. 
LT84 and LTC4 Levels During Anticoagulation with Low Molecular 
Heparin and Pretreatment With or Without Protamine 
and Subsequent Protamine Reversal 
Group I Group II Group I Group II 
LMWH, LMWH. LMWH, LMWH. 
Saline Protamine Saline Protamine 
Pretreatment Pretreatment Pretreatment Pretreatment 
LT84 (pg/mll pq/ml) LTC4( 
Baseline value 10252192 11192244 
After pretreatment 9522178 883+186 
After heparin 1111+z00 9922195 
before reversal (rev.) 
1 minute after rev. 1058+204 943+159 
3 minutes after rev. 969+99 8832258 
10 minutes after rev. 1057+254 1004+178 
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TABLE 7. 
Effects on Thrombin Clotting Time (TCT), 
Activated Partial Thromboplastin Time (APTT) and 
Bleeding Time During Anticoagulation With Standard Heparin 
or Lou Molecular Weight Heparin and Pretreatment With or without 
Protamine and Subsequent Protamine Reversal of Anticoagulation 
(Values Presented in Seconds) 
Baseline 2 Hin After Before After 
Value Anticoagulation Reversal Reversal 
- 
Group I (LMWH. Saline Pretreatment)_ 
TCT 6.220.2 53.6tB.5*** 21.9+3.3** 6.BkO.3 
APTT 13.651.5 36.1+13.0** 21.3+2.7* 13.6+_1.1 
Bleeding Time 130 385** 105 
- 
GrOUD II (LMWH. Protamine Pretreatment) 
TCT 6.820.4 10.4+1.0* 8.ltO.4* 6.020.3 
APTT 13.6+o.8 17.6+1.5** 15.6+1.6* 14.321.3 





GrouD III (SH. Saline Pretreatment) 
6.520.3 > 100*** > loo*** 6.420.4 
13.2k1.4 45.1+9.8*** 35.8+8.B** 13.022.0 
135 540** 115 
Data expressed as x + SEM; n=6 in each group 
*p<o.o5, **p<o.o1, ***p<O.OOl; no intergroup differences 
OISCUSSION 
Administration of protamine to reverse heparin anticoagulation has been 
associated with a number of potentially serious hemodynamic and hematologic 
side effects (9). The action of protamine related to these events is only 
partially understood. Anaphylactic and allergic type reactions to protamine 
rarely occur (lo), and other events have been implicated in most adverse 
reactions to protamine. 
Platelets may be involved in the pulmonary and pulse effects. We have 
recently shown that systemic hypotension develops to the same extent in 
thrombocytopenic dogs as in those with normal platelet counts. However, the 
pulmonary artery hypertension and bradycardia usually accompanying these 
events was not seen (4). This suggests that the hypotension and pulmonary 
effects are mediated by different mechanisms. In fact, vasodilation appears 
responsible for much of the initial hypotension. Earlier work from our 
laboratory also has demonstrated that small amounts of protamine given prior 
to heparin anticoagulation and its subsequent reversal abolished adverse 
hemodynamic effects and diminished the thrombocytopenia, although the 
leukopenia was not reduced. The latter finding all but excludes the 
possibility that leukocytes themselves cause the adverse side effects 
attending protamine reversal of heparin (1). 
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Failure to document alterations in antithrombin III or Q-2 macroglobulin 
levels in the current study suggests that thrombin generation or release of 
proteolytic enzymes is unlikely to be the major factor in causing the adverse 
effects of protamine. Other vasoactive substances, released for example from 
mast cells, could explain the effects of protamine administration. In this 
regard histamine release has been documented in these reactions (12). although 
histamine depletion or receptor blockage has not attenuated these responses 
(13). Results of Cl-esterase assays in the present study preclude a major 
alteration within the bradykinin-system in these reactions, although some 
increase in C-l-esterase inhibitor leveis was noted. Many investigators have 
suggested that complement activation by protamine mediates the adverse 
responses (14). With clinically relevant dosages of protamine in this 
experiment, as well as in earlier studies in dogs and humans, we have been 
unable to verify significant complement activation as the cause of the adverse 
effects (1.15). 
This investigation revealed an increase in thromboxane B2 after 
protamine reversal, perhaps a reflection of platelet aggregation and 
thromboxane release. 6-keto PGFl, levels also increased after protamine 
administration. In this regard, cyclooxygenase inhibitors prevent pulmonary 
artery hypertension, but do not affect the other responses accompanying 
protamine reversal of heparin (15). Thus, it is unlikely that prostanoids are 
the major cause of protamine's side effects. The leucotrienes did not show 
any change, but the likelihood that such are uninvolved cannot be claimed 
inasmuch as leucotrienes are bound to cells and albumin, both of which were 
extracted in the assay performed in this experiment. 
Another potential mechanism accounting for the action of protamine is that 
this basic protein alters cell membranes (10.17). SH has two specific binding 
sites on the endothelial cell membrane, with a higher affinity than LHWH 
(18). However, the adverse hemodynamic effects are not explained by this 
difference (2). Protamine reversal did not normalize the Anti-Xa levels 
achieved with LMWH. Protamine reversal of heparin normally causes a 
dissociation of heparin-antithrombin III complexes (3,19,20). If the short 
molecular chain of LMWH is unable to be dissociated, then the inability of Xa 
inhibition to be reversed can easily be explained. 
In conclusion, this study has documented that protamine reversal of LMWH 
or SH anticoagulation does not significantly alter the complement, bradykinin 
or leucotriene systems, but does cause mild platelet activation, prostacyclin 
release, and has variable effects on Xa inhibition depending on the type of 
heparin initially administered. Protamine reversal of LMWH when compared to 
SH did not reveal any clear differences in eicosanoids or complement factors, 
although XaI activity clearly separated these two heparins. 
REFERENCES 
1. WAKEFIELD. I.W., LINDBLAD, B., WHITEHOUSE, W.M. JR., HANTLER, C.B.. 
STANLEY, J.C. Attenuation of hemodynamic and hematologic effects of 
heparin-protamine sulfate interaction following aortic reconstruction in 
a canine model. Surgery 100, 45-51, 1986. -- 
2. LINDBLAO, B., BORGSTRBM, A., WAKEFIELD, T.W., WHITEHOUSE, W.M. JR., 
STANLEY, J.C. Hemodynamic and hematologic alterations with protamine 
reversal of anticoagulation: Comparison of standard heparin and a low 
molecular weight heparin fragment. Submitted. Eur J Vast Surg ____--.___.--.~ 














HOLHER, E., S%ERBERG, K., BERGQVIST, D., LINDAHL, U. Heparin and its 
low molecular weight derivates. Anticoagulant and antithrombotic 
properties. Haemostasis 12, 1-7, 1986. 
GANROT, P.O. Determination of a2-macroglobulin as trypsin-protein 
esterase. Clin. Chim. Acta 12, 493-501, 1966. 
GALLIMORE, M.J., FRIBERGER, P. Simple chromogenic peptide substrate 
assays for determining prekallikrein, kallikrein inhibition and 
kallikrein "like" activity in human plasma. Thromb. Res. 25, 293-298, 
1982. 
ABILDGAARD, U., LIE, N., ODEGARD, 0-R. Antithrombin (heparin cofactor) 
assay with "new" chromogenic substrates (S-2238 and Chromozym TH). 
Thromb. Res. l_l. 549-553, 1977. - 
TEIEN, A.N., LIE, H., ABILDGAARD, U. Assay of heparin in plasma using a 
chromogenic substrate for activated factor X. Thromb. __ ~~~ Res. 0_, 413-416. 
1976. 
80G-HANSEN, T.C., HAU, J. Affinity electrophoresis of glycoproteins. 
Acta. Histochem. (Jena) 71, 47-56. 1982. 
WAKEFIELD, T.W., WHITEHOUSE, W.M. JR., STANLEY, J.C. Depressed 
cardiovascular function and altered platelet kinetics following protamine 
sulfate reversal of heparin activity. J. Vast. Surg. A, 346-355, 1984. ~---- 
HORROW, J.C. Protamine: A review of its toxicity. Anesth. Analg. fL4, 
348-361, 1985. 
LINDBLAD, 8., WAKEFIELD, T-W.. WHITEHOUSE, W.N. JR., STANLEY, J.C. 
Platelets and the effects of protamine. Thromb. Haemostas. 54, 
(Abstract), 1985. 
SCHiiSTER, V.J., KUNZE, J. Zur Frage der Mastzelldegranulation durch 
Compound 48.80. Tachyphylaxie der isolierten Mastzelle gegen 48/80, 
Hermnung der Degranulation durch Heparinoide, Beeinflussung der 
Tachyphylaxie durch Protamin. Arzneimittelforschung a:589-591, 1969. --.-... ___.____.~ . 
FRATER, R.W.M., OKA, Y., HONG, Y., TSUBO. T., LOUBSER, P.G.. MASONE, R. 
Protamine-induced circulatory changes. J. Thorac. Cardiovasc. Surg. 87_, I-_.._-.-.~~ ._ 
687-692. 1984. 
BEST. N.. SINOSICH, H.J., TEISNER, 8.. GRUDZINKAS, J.G., FISHER, H.M. 
Complement activation during cardiopulmonary bypass by heparin-protamine 
interaction. Dr. J. Anaesth 5_6. 339-343, 1984. 
WAKEFIELD, T.W., HANTLER, C.B., LINDBLAD, 8.. WHITEHOUSE. W.H. JR., 
STANLEY, J.C. Protamine pretreatment attenuation of hemodynamic and 
hematologic effects of heparin-protamine interaction. A prospective 
randomized study in human beings undergoing aortic reconstructive 
surgery. J. Vast. Surg. 3. 885-889. 1986. 
40 PROTAMINE AND LMW HEPARIN Vol. 48, No. 1 
16. RADEGRAN, K., McASLAN, C. Circulatory and ventilatory effects of induced 
platelet aggregation and their inhibition by acetylsalicylic acid. @ 
Anaesth. Scani. 16. 76-84. 1972. 
17. DRYJSKI, M., LARSSON, R., OLSSON, P., SWEDENBORG. 3. Effect of 
glycosaminoglycans and antithrombin III on uptake and inhibition of 
thrombin by the vascular wall. Thromb. Res. 32, 355-363, 1983. 
18. EARZU, T., HOLHO, P., TOEELEM, G., PETITOU, M., CAEN, J.P. Binding of 
heparin and low molecular weight heparin fragments to human vascular 
endothelial cells in culture. Nouv. Rev. Fr. Hematol. 26, 243-247. 1984. 
19. LANE, D.A., DENTON, J., FLYNN, A.M., THUNBERG, L., LINDAHL, U. 
Anticoagulant activities of heparin oligosaccharides and their 
neutraliziation by platelet factor 4. Biochem. J. 218, 725-732. 1984. 
20. HARENEERG, 3.. GNASSO, A., DE VRIES, J.X., ZIMMERMANN, R., AUGUSTIN, J. 
Inhibition of low molecular weight heparin by protamine chloride in 
vivo. Thromb. Res 32, 11-20. 1985. 
